Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Pilatus Biosciences Inc

Clinical trials sponsored by Pilatus Biosciences Inc, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New antibody drug takes aim at Hard-to-Treat cancers Results expected Sep 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

New antibody drug takes aim at Hard-to-Treat cancers

Disease control Recruiting now

This early-stage trial is testing a new drug called PLT012 in adults with advanced solid tumors that have not responded to standard treatments. PLT012 is an antibody that targets a protein called CD36 found on some cancer cells. The main goals are to find safe doses and to see if…

Phase 1 • Sponsor: Pilatus Biosciences Inc • Aim: Disease control

Last updated Jul 09, 2026 00:00 UTC